TB R&D Weekly Update: Tyrosine Kinases as Therapeutic Targets against TB

Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, Bornmann W, Salgame P, Shinnick TM, Kalman D. Imatinib-Sensitive Tyrosine Kinases Regulate Mycobacterial Pathogenesis and Represent Therapeutic Targets against Tuberculosis. Cell Host Microbe. 2011 Nov 17;10(5):475-85.

This week’s article looks at host factors that contribute to the ability of Mycobacterium tuberculosis (Mtb) to enter and survive within macrophages. The authors explore the role of tyrosine kinases (TKs) as a mediator for Mtb and the use of an inhibitor of TKs to act against Mtb and related bacteria. Key points from the article are:

  • Data from experiments using TK inhibitors and cell lines from knockout animals show that there is a role for specific TKs in Mtb and related bacteria’s processes for entry and intracellular survival. Also, it appears multiple kinases mediate intracellular survival within macrophages.
  • Imatinib, an inhibitor of some TKs and used in cancer therapy, was shown to reduce bacterial loads in macrophages and mice infected with Mtb or M. marinum. Imatinib also seems to have synergy with drugs like rifampicin and rifabutin.
  • There has been low toxicity reported in patients although there is some reported toxicity in patients taking imatinib with long-term exposure. This may suggest looking at imatinib as a therapeutic against active TB or reactivated TB. The benefit of targeting the host with imatinib is that the bacteria would need to make a major adaptation to develop resistance and also could confer some protection to current first-line drugs by reducing the bacterial burden below the spontaneous mutation frequency.

Additional TB R&D News:

SRI Researchers Validate Preclinical Effectiveness of Tuberculosis Drug Target that Could Shorten Treatment Time

Hyderabad scientists discover TB bacteria killer

Eli Lilly and Company Provides IDRI with Additional Funding for Identification of New Tuberculosis Therapies

Tuberculosis – Novel Tools And Coordination Required

Webcams Connect TB Patients to Public Clinic for Treatment Compliance

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...